PP
BIO icon

PDT Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

PDT Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-501
Closed -$248K – 851
2022
Q2 		$248K Buy
+501
New +$261K 0.02% 787
2015
Q3 		– Sell
-5,411
Closed -$815K – 1274
2015
Q2 		$815K Buy
+5,411
New +$774K 0.02% 802
2014
Q4 		– Sell
-15,472
Closed -$1.75M – 665
2014
Q3 		$1.75M Buy
+15,472
New +$1.83M 0.04% 460
2013
Q4 		– Sell
-2,700
Closed -$317K – 674
2013
Q3 		$317K Sell
2,700
-5,869
-68% -$692K 0.01% 1225
2013
Q2 		$961K Buy
+8,569
New +$1.01M 0.02% 830

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PDT Partners's BIO Position: Q3 2022 in Review

PDT Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 501 shares — an estimated $248K sold.

PDT Partners first reported a position in BIO in Q2 2013 and held it in 5 quarters. The position peaked at $1.75M in Q3 2014. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • PDT Partners reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 501 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $248K.
  • PDT Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 5 quarters.
  • PDT Partners's Bio-Rad Laboratories Class A position peaked at $1.75M in Q3 2014.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.